Outlook Therapeutics
OTLK
76 hedge funds and large institutions have $25.4M invested in Outlook Therapeutics in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 24 increasing their positions, 24 reducing their positions, and 12 closing their positions.
25% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 12
3% more funds holding
Funds holding: 74 → 76 (+2)
0% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 24
0.33% less ownership
Funds ownership: 11.35% → 11.01% (-0.33%)
35% less capital inflows, than outflows
Capital inflows: $1.83M | Capital outflows: $2.8M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$396K |
| 2 |
State Street
Boston,
Massachusetts
|
+$320K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$278K |
| 4 |
LPL Financial
San Diego,
California
|
+$72.6K |
| 5 |
Lincoln National Corp
Radnor,
Pennsylvania
|
+$71.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$744K |
| 2 |
Two Sigma Investments
New York
|
-$420K |
| 3 |
Two Sigma Advisers
New York
|
-$275K |
| 4 |
Nuveen
Charlotte,
North Carolina
|
-$169K |
| 5 |
Jane Street
New York
|
-$145K |
OTLK Hedge Fund Activity: Q2 2022 in Review
76 of the 5,963 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q2 2022, worth a combined $25.4M — down 44% from $45.5M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new OTLK positions and 12 closed out — a net gain of 3 holders — while 24 added to existing stakes and 24 trimmed.
The largest buyer was BlackRock, adding an estimated $396K. The largest seller was Renaissance Technologies, cutting an estimated $744K.
- 76 institutional investors held Outlook Therapeutics (OTLK) as of Q2 2022, up from 74 in Q1 2022.
- Funds reported $25.4M of Outlook Therapeutics stock for Q2 2022, down 44% quarter-over-quarter.
- 15 funds opened new Outlook Therapeutics positions in Q2 2022 and 12 closed out, a net change of +3 holders.
- The largest Outlook Therapeutics buyer in Q2 2022 was BlackRock, an estimated $396K added.
- The largest Outlook Therapeutics seller in Q2 2022 was Renaissance Technologies, an estimated $744K sold.
Based on aggregated 13F filings for Q2 2022.